This research report “Women’s Health Cluster Drug Development Pipeline Review, 2017” provides an overview of the women’s health pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for female infertility, polycystic ovarian syndrome and endometriosis, and also feature dormant and discontinued projects.
Complete research report of 123 pages including 103 List of Tables and 32 List of Figures is available at https://www.marketinsightsreports.com/reports/051811079/women-s-health-cluster-drug-development-pipeline-review-2017
Companies involved in therapeutic development are 4P Therapeutics LLC, AbbVie Inc, Addex Therapeutics Ltd, AlphaMab Co Ltd, APAvadis Biotechnologies Srl, ASKA Pharmaceutical Co Ltd, Astellas Pharma Inc, Bayer AG, Dong-A Socio Holdings Co Ltd, Dongkook Pharmaceutical Co Ltd, ElexoPharm GmbH, EndoCeutics Inc, Enteris BioPharma Inc, Evotec AG, Ferring International Center SA, Forendo Pharma Ltd, Glycotope GmbH, Isifer AB, Kissei Pharmaceutical Co Ltd, Lipicard Technologies Ltd, Livzon Pharmaceutical Group Inc, Luye Pharma Group Ltd, Merck & Co Inc, Navya Biologicals Pvt Ltd, Nippon Shinyaku Co Ltd, Nora Therapeutics Inc, ObsEva SA, Ogeda SA, Orphagen Pharmaceuticals Inc, Pangen Biotech Inc., Pantec Biosolutions AG, PharmaEssentia Corp, Philogen SpA, Repros Therapeutics Inc, Richter Gedeon Nyrt, SK Chemicals Co Ltd, Takeda Pharmaceutical Company Ltd, TocopheRx Inc, ValiRx Plc, Viramal Ltd and Zydus Cadila Healthcare Ltd.
Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. There are a total of 12 products in development for this indication, by eight companies and three academic institutions. A number of companies are operating in this space, with EffRx alone developing multiple programs within the area.
Any questions? Feel free to reach us at https://www.marketinsightsreports.com/reports/051811079/women-s-health-cluster-drug-development-pipeline-review-2017/inquiry
Finally, endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (the endometrium) grows outside the uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. There are a total of 53 products in development for this indication, by 29 companies and eight academic institutions. Key companies operating in this pipeline space include Bayer and Evotec, which are each developing five distinct programs in this disease area.
Generally the main types of therapy being developed act on hormone receptors, reflecting the hormone-driven pathophysiology of this disease area. However, particularly in polycystic ovarian syndrome, a broader range of molecular targets, such as intracellular protein kinases, chemokine receptors and other cell signaling components are also targeted.
Scope of this research: Which companies are the most active within the pipeline for women’s health therapeutics? Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? What are the most important R&D milestones and data publications to have happened in the field of women’s health therapeutics?
This research will help you to:-
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration